Abstract
Last month, Indivior and Reckitt Benckiser agreed to a settlement in which Indivior was released from indemnity under the demerger (spinoff) agreement and, in exchange, will give Reckitt Benckiser $50 million over the next five years. Indivior owns Suboxone and Sublocade. The Department of Justice and the Federal Trade Commission settled with Reckitt Benckiser in 2019 due to patent switch issues when buprenorphine‐naloxone finally, despite the manufacturer's attempts to prevent it, went generic (see “RB agrees to pay U.S. $1.4 billion for avoiding prosecution over Suboxone marketing scheme; Indivior trial next year,” ADAW July 22, 2019; https://onlinelibrary.wiley.com/doi/10.1002/adaw.32431). Now, Reckitt Benckiser is getting that money back from Indivior. Indivior announced that its “vision is that all patients around the world will have access to evidence‐based treatment for the chronic conditions and co‐occurring disorders of addiction” and it “is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.” Going forward, this will mean expanding on treatment for alcohol use disorder, according to the Richmond, Virginia–based company. Indivior was spun off from Reckitt Benckiser, which developed Suboxone with full government funding because this was an “orphan” drug, beginning in 1994 (see “Buprenorphine a focus of hearing on government support for medications,” ADAW June 28, 2010; https://onlinelibrary.wiley.com/doi/10.1002/adaw.20239).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
